Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Gendicine for Multiple Ground-Glass Lung Nodules
NCT07150416Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rAdp53 in lung adenocarcinoma, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective Response Rate at 6 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
rAdp53
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT07150416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150416.